EchoNous vs Lunit
Kosmos's AI page lists five features: bladder volume, ejection fraction with manual override, Doppler gate placement at the LVOT and three valves, FAST view labeling with fluid location, and preset switching. The 2024 PANES-HF study tested AI-supported echocardiography by novices for heart failure screening. That setting fits a hospital medicine service or primary care clinic with no sonographer on site.
Breast imaging groups reading screening mammograms and tomosynthesis are the Lunit buyer. FDA's list for Lunit, Inc. holds two INSIGHT MMG entries and three INSIGHT DBT entries, the latest in April 2026. INSIGHT MMG and CXR also hold CE and UKCA marks under MDR, announced in November 2022. A hospital medicine service and a breast imaging group do not make the same purchase. For chest films, the vendor's page describes 11 thoracic abnormalities for INSIGHT CXR, while FDA's list shows the chest tool only as INSIGHT CXR Triage.
Radiology · Reviewed November 2, 2026
EchoNous
by EchoNous Inc. · founded 2016
Kosmos handheld ultrasound with AI bladder volume, ejection fraction, Doppler gate and FAST view guidance.
Lunit
by Lunit · founded 2013
AI for chest X-ray, mammography and breast tomosynthesis, Volpara breast-density tools, and pathology biomarker software (SCOPE).
When to pick each one
EchoNous
- Five AI features listed on the Kosmos AI page
- Novice heart failure screening studied in PANES-HF
Lunit
- Mammography and tomosynthesis tools with FDA records
- CE marks under EU MDR for CXR and MMG
Score
Each row shows points earned of points available under the published rubric.
EchoNous
78of 100
Lunit
66of 100
| Dimension | EchoNous | Lunit | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 10 / 10 | 0 / 10 | +10 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 18.2 / 18.2 | 12.7 / 18.2 | +5.5 |
| RCT / meta-analysis / systematic review | 7.8 / 7.8 | 7.8 / 7.8 | 0 |
| Funding & adoption signal | 3 / 12 | 8.4 / 12 | -5.4 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 6 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
EchoNous
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. The vendor says Kosmos Plus costs less than $20k. |
Lunit
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Contact form only. |
Evidence
EchoNous
FDA decisions
K242321 (opens in new tab)510(k)2025-04-25
Kosmos
K233826 (opens in new tab)510(k)2024-08-29
Kosmos
K212100 (opens in new tab)510(k)2021-08-06
Kosmos
K193518 (opens in new tab)510(k)2020-03-26
KOSMOS
Peer-reviewed
5 PubMed records name EchoNous.
- Army Medic Performance in Trauma Sonography: The Impact of Artificial Intelligence Assistance in Focused Assessments With Sonography in Trauma-A Prospective Randomized Controlled Trial. (opens in new tab)
- Point-of-care AI-enhanced novice echocardiography for screening heart failure (PANES-HF). (opens in new tab)
- Validation of a hand-held ultrasound device in the evaluation of aortic stenosis. (opens in new tab)
Lunit
FDA decisions
K260320 (opens in new tab)510(k)2026-04-23
Lunit INSIGHT MMG (v1.1.10)
K253796 (opens in new tab)510(k)2026-03-26
Lunit INSIGHT DBT (V1.2)
K242652 (opens in new tab)510(k)2024-10-04
Lunit INSIGHT DBT v1.1
K231470 (opens in new tab)510(k)2023-11-06
Lunit INSIGHT DBT
K211678 (opens in new tab)510(k)2021-11-17
Lunit INSIGHT MMG
Show 3 more
K211733 (opens in new tab)510(k)2021-11-10
Lunit INSIGHT CXR Triage
K211279 (opens in new tab)510(k)2021-07-27
Volpara Imaging Software
K182310 (opens in new tab)510(k)2018-09-21
Volpara Imaging Software
Peer-reviewed
3 PubMed records name Lunit.
- Comparison of different Lunit INSIGHT CXR software versions when reading chest radiographs for tuberculosis. (opens in new tab)
- Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21). (opens in new tab)
- Long-term prognostic implications of AI-detected versus AI-undetected breast cancers on mammography: a propensity score-matched analysis. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | EchoNous | Lunit |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2016 | 2013 |
| HQ | US | KR |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.